Experienced in Congenital Antithrombin 3 Deficiency

Dr. Monisha Singh

Oncology | Hematology | Hematology Oncology
Tmh Physician Associates PLLC
7575 San Felipe St, Suite 155, 
Houston, TX 
Accepting New Patients
Offers Telehealth
Experienced in Congenital Antithrombin 3 Deficiency
Tmh Physician Associates PLLC
7575 San Felipe St, Suite 155, 
Houston, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Monisha Singh is an Oncologist and a Hematologist in Houston, Texas. Dr. Singh is rated as an Experienced provider by MediFind in the treatment of Congenital Antithrombin 3 Deficiency. Her top areas of expertise are Endometrial Cancer, Familial Pancreatic Cancer, Breast Cancer, Paget Disease of the Breast, and Bone Marrow Aspiration. Dr. Singh is currently accepting new patients.

Her clinical research consists of co-authoring 3 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Hematology Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
Houston Methodist Clear Lake Hospital
Houston Methodist Hospital
Houston Methodist Baytown Hospital
Houston Methodist The Woodlands Hospital
Houston Methodist Sugarland Hospital
Languages Spoken
English
Spanish
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

TMH PHYSICIAN ASSOCIATES PLLC
7575 San Felipe St, Suite 155, Houston, TX 77063
Other Locations
TMH PHYSICIAN ASSOCIATES PLLC
16605 Southwest Fwy 400 Mob3, Methodist Family Medicine, Sugar Land, TX 77479
TMH PHYSICIAN ASSOCIATES PLLC
6445 Main St, Houston, TX 77030
TMH PHYSICIAN ASSOCIATES PLLC
4710 Bellaire Blvd, Bellaire, TX 77401
TMH PHYSICIAN ASSOCIATES PLLC
6565 Fannin St, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cediranib Maleate, Durvalumab, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Study Phase: Phase 2
A Pilot Study of Hydroxytyrosol, a Component of Olive Oil for Breast Cancer Prevention In Women At High Risk Of Breast Cancer
A Pilot Study of Hydroxytyrosol, a Component of Olive Oil for Breast Cancer Prevention In Women At High Risk Of Breast Cancer
Enrollment Status: Completed
Publish Date: October 10, 2023
Intervention Type: Drug
Study Drug: Hydroxytyrosol
Study Phase: Phase 2/Phase 3
Phase II Study of The Efficacy And Safety of Chloroquine (C) in CombinAtion With Taxane or Taxane-like (T) Chemo Agents in The Treatment of Patients With Advanced or Metastatic Breast Cancer Who Have Failed Anthracycline Chemo Base Therapy
Phase II Study of The Efficacy And Safety of Chloroquine (C) in CombinAtion With Taxane or Taxane-like (T) Chemo Agents in The Treatment of Patients With Advanced or Metastatic Breast Cancer Who Have Failed Anthracycline Chemo Base Therapy
Enrollment Status: Completed
Publish Date: January 23, 2023
Intervention Type: Drug
Study Phase: Phase 2
Randomized Open Label PhII Trial of Neoadjuvant Trastuzumab Emtansine(Te) in Combination w/Lapatinib(L) Followed by Abraxane (A) Compared w/Trastuzumab Plus Pertuzumab Followed by Paclitaxel in Her2/Neu Over-Expressed Breast Cancer Patients
Randomized Open Label PhII Trial of Neoadjuvant Trastuzumab Emtansine(Te) in Combination w/Lapatinib(L) Followed by Abraxane (A) Compared w/Trastuzumab Plus Pertuzumab Followed by Paclitaxel in Her2/Neu Over-Expressed Breast Cancer Patients
Enrollment Status: Completed
Publish Date: September 22, 2021
Intervention Type: Drug
Study Phase: Phase 2
Neoadjuvant Phase II Study Of Everolimus Plus Cisplatin In Triple Negative Breast Cancer Patients With Residual Disease After Standard Chemotherapy
Neoadjuvant Phase II Study Of Everolimus Plus Cisplatin In Triple Negative Breast Cancer Patients With Residual Disease After Standard Chemotherapy
Enrollment Status: Completed
Publish Date: July 20, 2021
Intervention Type: Drug
Study Phase: Phase 2
Phase Ib Trial of Trastuzumab Emtansine In Combination With Lapatinib Plus Abraxane In Metastatic Her 2 Neu Over-Expressed Breast Cancer Patients
Phase Ib Trial of Trastuzumab Emtansine In Combination With Lapatinib Plus Abraxane In Metastatic Her 2 Neu Over-Expressed Breast Cancer Patients
Enrollment Status: Completed
Publish Date: April 16, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 5 Less Clinical Trials

3 Total Publications

Impact of Infections in Patients Receiving Pembrolizumab-Based Therapies for Non-Small Cell Lung Cancer.
Impact of Infections in Patients Receiving Pembrolizumab-Based Therapies for Non-Small Cell Lung Cancer.
Journal: Cancers
Published: December 04, 2022
Similar Doctors
Advanced in Congenital Antithrombin 3 Deficiency
Dr. Samer S. Suki
Hematology Oncology | Oncology | Hematology
Advanced in Congenital Antithrombin 3 Deficiency
Dr. Samer S. Suki
Hematology Oncology | Oncology | Hematology

Texas Oncology PA

22710 Professional Dr, Suite 100, 
Kingwood, TX 
 (25.3 miles away)
281-296-0365
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Samer Suki is a Hematologist Oncology specialist and an Oncologist in Kingwood, Texas. Dr. Suki is rated as a Distinguished provider by MediFind in the treatment of Congenital Antithrombin 3 Deficiency. His top areas of expertise are Childhood Iron Deficiency Anemia, Paget Disease of the Breast, Pleuropulmonary Blastoma, and Lung Cancer. Dr. Suki is currently accepting new patients in some locations.

Advanced in Congenital Antithrombin 3 Deficiency
Dr. Luis H. Camacho
Hematology Oncology | Hematology | Oncology
Advanced in Congenital Antithrombin 3 Deficiency
Dr. Luis H. Camacho
Hematology Oncology | Hematology | Oncology
6560 Fannin St, Suite 1224, 
Houston, TX 
 (6.7 miles away)
713-796-1200
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Luis Camacho is a Hematologist Oncology specialist and a Hematologist in Houston, Texas. Dr. Camacho is rated as an Advanced provider by MediFind in the treatment of Congenital Antithrombin 3 Deficiency. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Pleuropulmonary Blastoma, and Urothelial Cancer.

Advanced in Congenital Antithrombin 3 Deficiency
Dr. Murtaza N. Bhuriwala
Hematology Oncology | Oncology
Advanced in Congenital Antithrombin 3 Deficiency
Dr. Murtaza N. Bhuriwala
Hematology Oncology | Oncology

Texas Oncology PA

22710 Professional Dr, Suite 100, 
Kingwood, TX 
 (25.3 miles away)
281-296-0365
Languages Spoken:
English, Arabic, French, Hindi, Sindhi, Spanish, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Murtaza Bhuriwala is a Hematologist Oncology specialist and an Oncologist in Kingwood, Texas. Dr. Bhuriwala is rated as an Advanced provider by MediFind in the treatment of Congenital Antithrombin 3 Deficiency. His top areas of expertise are Childhood Iron Deficiency Anemia, Pleuropulmonary Blastoma, POEMS Syndrome, Protein S Deficiency, and Orchiectomy. Dr. Bhuriwala is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Singh's expertise for a condition
ConditionClose
    View All 27 Advanced Conditions
    View All 75 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile